side outside the country, you're likely to see slightly better results because marge ps are lower, there is more room for up sight and evaluations are -- >> evaluations are better. that doesn't mean that you don't have choices to share with the viewers. let's start with the first one. tell us what will drive that stock to better gains this year. >> well as you know, gilliad has two specialty drugs among a lot of the other ones that they have, but the key ones that is really driving the stock is the hiv drug as well as the new one that they have created for hepatitis c. and the early test results for that hepatitis c drug are very, very positive and that's an untapped market if the look at the u.s. market. there is about 4 million folks estimated in the country to have hepatitis c. so that creates a big market for them, and that's just the u.s. that's not to mention the global market potential out there. so it's a pretty good growth story. the stock has run in 2013 but we think there is more room. >> let's get the next three in. you go old school with the next pick. >> yeah, you know, the